Home › Funds › Commodore Capital LP › CLDX
Commodore Capital LP position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Commodore Capital LP reported holding 1,350,000 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$50.2M, representing 2.99% of its reported portfolio and ranking #13 among its reported holdings. Commodore Capital LP has disclosed CLDX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Commodore Capital LP's CLDX position evolved
Commodore Capital LP first disclosed a stake in CLDX in Q3 2023 at 706,665 shares (US$19.4M). The position peaked in Q1 2026 at 2,696,616 shares, worth US$85.5M. Across 11 filings, Commodore Capital LP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,350,000 shares valued at US$50.2M — a reduction of -1,346,616 shares quarter over quarter.. Notable position changes include a 64% increase in Q2 2024 (shares fell 8% over the following quarter), a 50% trim in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 706.66K | $19.45M | New |
| Q4 2023 | 701.97K | $27.84M | Reduce |
| Q1 2024 | 866.47K | $36.37M | Add |
| Q2 2024 | 1.43M | $52.74M | Add |
| Q3 2024 | 1.62M | $55.03M | Add |
| Q1 2025 | 3.20M | $58.08M | New |
| Q2 2025 | 3.45M | $70.21M | Add |
| Q3 2025 | 3.03M | $78.34M | Reduce |
| Q4 2025 | 2.56M | $69.67M | Reduce |
| Q1 2026 | 2.70M | $85.54M | Add |
| Q2 2026 | 1.35M | $50.23M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 43 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.32M sh · $198.07M · Q2 2026
- Deep Track Capital, LP 2.94M sh · $109.37M · Q2 2026
- Logos Global Management LP 2.10M sh · $78.14M · Q2 2026
- Eversept Partners, LP 1.79M sh · $66.45M · Q2 2026
- Bellevue Group AG 1.20M sh · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Elmind Capital, LP 990.00K sh · $36.84M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- Affinity Asset Advisors, LLC 700.00K sh · $26.05M · Q2 2026
- Rock Springs Capital Management LP 699.15K sh · $26.02M · Q2 2026
- ADAR1 Capital Management, LLC 619.54K sh · $23.05M · Q2 2026
More on Commodore Capital LP
FAQ
How long has Commodore Capital LP held CLDX?
Commodore Capital LP has disclosed CLDX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
What is Commodore Capital LP's current position in CLDX?
As of Q2 2026, Commodore Capital LP holds 1.35M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $50.23M, representing 2.99% of its reported portfolio and ranking #13.
Has Commodore Capital LP been buying or selling CLDX?
In the latest 13F filing (Q2 2026), Commodore Capital LP reduced its position in CLDX. The position peaked in Q1 2026 at 2.70M shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.